Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingmai Granule is a Traditional Chinese Medicine (TCM) formulation developed by the Institute of Vascular Diseases at the Tianjin Hospital of Integrated Traditional Chinese and Western Medicine (Nankai Hospital). It is primarily indicated for the treatment of chronic peripheral vascular diseases, such as thromboangiitis obliterans (Buerger's disease) and arteriosclerosis obliterans. The formula is designed to clear heat, detoxify, and promote blood circulation. Beyond its primary vascular indications, research has demonstrated that Qingmai Granule possesses hepatoprotective properties, particularly against liver damage induced by ischemia-reperfusion or chemical toxins. Its mechanism of action involves the inhibition of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and the suppression of the NF-kappaB signaling pathway, thereby reducing oxidative stress and inflammatory tissue injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingmai granule.